Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|November 17, 2023

Myelodysplastic Syndrome (MDS) Overview

Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state.

Episodes in this series

EP. 1 Myelodysplastic Syndrome (MDS) Overview

EP. 1 Myelodysplastic Syndrome (MDS) Overview

EP. 2 Distinguishing Between Different MDS Subtypes

EP. 2 Distinguishing Between Different MDS Subtypes

EP. 3 MDS-Related Complications Impacting Patient Quality of Life

EP. 3 MDS-Related Complications Impacting Patient Quality of Life

EP. 4 Economic Implications of MDS Management

EP. 4 Economic Implications of MDS Management

EP. 5 Examining Treatment Algorithms for MDS

EP. 5 Examining Treatment Algorithms for MDS

EP. 6 Growth Factor and Stem Cell Transplant Candidacy in MDS

EP. 6 Growth Factor and Stem Cell Transplant Candidacy in MDS

EP. 7 Novel Agents Contributing to Evolving MDS Therapy Strategies

EP. 7 Novel Agents Contributing to Evolving MDS Therapy Strategies

EP. 8 Benefits of Oral Therapies In MDS Treatment Adherence

EP. 8 Benefits of Oral Therapies In MDS Treatment Adherence

EP. 9 Adapting MDS Treatment Approach

EP. 9 Adapting MDS Treatment Approach

EP. 10 Novel Therapy Impact on Patient Quality of Life

EP. 10 Novel Therapy Impact on Patient Quality of Life

Video 11 - "Multidisciplinary Care Driving Effective MDS Treatment"

EP. 11 Multidisciplinary Care Driving Effective MDS Treatment

Video 12 - "Payor Considerations In MDS Management"

EP. 12 Payor Considerations In MDS Management

Video 12 - "Payor Considerations In MDS Management"

EP. 13 Navigating Insurance-Related Challenges Associated With MDS Treatment

Video 12 - "Payor Considerations In MDS Management"

EP. 14 Key Considerations Surrounding MDS Treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Kevin Kaiserman, MD

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

ByGiuliana Grossi,Kevin Kaiserman, MD

June 5th 2026

Rising piles of coins indicating cost savings | Image credit: THAWEERAT - stock.adobe.com

Delgocitinib Coverage Could Save Health Plans $88M Over 3 Years

ByLaura Joszt, MA

June 5th 2026

Noah Greenspan, DPT

COVID Postexposure Prophylaxis Expands Prevention Toolkit: Noah Greenspan, DPT, PT

BySabrina McCrear,Noah Greenspan, DPT, PT, CCS, EMT-B

June 5th 2026

Doctor writes a script for asthma. | Image credit: @Goffkein - stock.adobe.com

SUNRISE Trial: Tezepelumab Reduces Steroid Use in Severe Asthma

BySabrina McCrear

June 5th 2026

tryptophan and nuts | Image credit: Danijela - stock.adobe.com

Disrupted Tryptophan Metabolism Linked to Psoriasis Severity, Multiple Comorbidities

BySkylar Jeremias

June 5th 2026

Trending on AJMC

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

AI Reshaping Diabetes Care From Nutrition to Clinical Decisions

Contributor: How to Pair Data With Clinical Care to Manage Health Care Costs

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD